© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

Connecticut Alzheimer's Treatment Headed to Clinical Trials

Harriet Jones
/
WNPR
A prototype of the device Knight hopes will combat Alzheimer's Disease.

    

An invention to treat Alzheimer’s Disease, patented by a Connecticut entrepreneur, could now be in human clinical trials before the end of this year. The development comes just months after the launch of the technology.

Back in May, serial entrepreneur and inventor Eric Knight unveiled a device that he hopes will stem the neural degeneration caused by Alzheimer’s Disease and help sufferers preserve brain function. He’s not a medical man, but he does have expertise in radio frequency technology.

The device, which is designed to be worn on the patient’s head for an hour or so each day, directs radio waves at the brain, an idea based on research carried out in mice, which appeared to be highly effective in slowing the progress of the disease. 

Knight said the original research in mice was carried out by Dr. Gary Arendash, “who is by all measures the leading scientist in the world in the research of RF technologies in the treatment of Alzheimer’s Disease." Arendash is the senior editor of the Journal of Alzheimer’s Disease.

Now Arendash is the person who’s licensing Knight’s device for use in a human clinical trial that will hopefully get off the ground in Arizona this winter.

“So the validation of a company like that, headed by such an esteemed individual, to license my technology, was just an incredible validation of the technology that I developed,” Knight told WNPR.

Knight and Arendash only met after the Connecticut inventor had patented his device, but the two hit it off immediately, arranging the licensing deal in only a few weeks.

“In medical science, things don’t normally happen that fast. So really to be able to create this license with this company, and to be able to hopefully be testing this on humans sometime this winter is really warp speed,” Knight said.

This may not be the only license Knight receives for his device. He says he currently has five other inquiries, and he’ll follow up on all of them. He hopes to be able to fast track work on his idea, with the aim of making an impact on a disease that affects as many as 5 million Americans.

Harriet Jones is Managing Editor for Connecticut Public Radio, overseeing the coverage of daily stories from our busy newsroom.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content